Want to see IKT full AI Analyst Report?
IKT Stock Chart & Stats
$1.83
$0.06(1.71%)
At close: 4:00 PM EST
$1.83
$0.06(1.71%)
Day’s Range― - ―
52-Week Range$1.33 - $2.36
Previous CloseN/A
Volume38.02K
Average Volume (3M)132.72K
Market Cap
$278.59M
Enterprise Value$119.11
Total Cash (Recent Filing)$170.37M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.62
Next Earnings
Aug 17, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding132,032,640
10 Day Avg. Volume124,469
30 Day Avg. Volume132,718
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.17
Price to Sales (P/S)0.00
P/FCF Ratio-7.25
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.00Price Target Upside227.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.42
Revenue Forecast (FY)$375.00K
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet And Minimal DebtA low-debt, equity-rich balance sheet reduces near-term refinancing risk for a development-stage biotech. With roughly $168M in equity and effectively zero debt, management has financial flexibility to fund clinical programs and negotiate partnerships without imminent pressure from lenders, supporting execution through pivotal milestones.
Recent $50M ATM Financing Extends RunwayThe $50M at-the-market raise materially extends operational runway toward the Part B topline readout of the global Phase 3 IMPROVE-PAH study. This capital reduces short-term funding risk, allowing completion of a pivotal clinical milestone that will determine regulatory and commercial paths, a durable driver of enterprise value.
Governance Changes Support Talent Retention And OversightApproval to expand the equity incentive plan and governance measures preserves management flexibility to retain and motivate key executives through equity compensation. For a late-stage clinical company, sustained leadership stability and alignment via awards are important to execute complex regulatory and commercialization plans over the medium term.
Bears Say
No Revenue And Sizable Net LossesThe company remains pre-revenue with large recurring losses, indicating value is fully contingent on clinical success rather than stable cash flows. Persistent negative earnings constrain internal funding capacity and heighten reliance on milestone outcomes; failure to achieve trial goals would materially impair long-term viability.
Sustained High Cash Burn And Negative Free Cash FlowOperating and free cash flow have been materially negative, implying the company must use cash reserves or raise capital to sustain operations. Continued high burn rates consume equity and limit optionality; absent partnering or a successful commercialization path, cash depletion remains a structural constraint on strategy and growth.
Reliance On Equity Raises And Dilution RiskFrequent or large equity financings are evidence the company depends on capital markets to fund development. This dilutes existing shareholders and signals limited near-term internal cash generation. Over the medium term, recurring equity issuance can compress per-share economics absent decisive clinical or commercial success.
Inhibikase Therapeutics News
IKT FAQ
What was Inhibikase Therapeutics’s price range in the past 12 months?
Inhibikase Therapeutics lowest stock price was $1.33 and its highest was $2.36 in the past 12 months.
What is Inhibikase Therapeutics’s market cap?
Inhibikase Therapeutics’s market cap is $278.59M.
When is Inhibikase Therapeutics’s upcoming earnings report date?
Inhibikase Therapeutics’s upcoming earnings report date is Aug 17, 2026 which is in 29 days.
How were Inhibikase Therapeutics’s earnings last quarter?
Inhibikase Therapeutics released its earnings results on May 12, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.108 by $0.008.
Is Inhibikase Therapeutics overvalued?
According to Wall Street analysts Inhibikase Therapeutics’s price is currently Undervalued.
Does Inhibikase Therapeutics pay dividends?
Inhibikase Therapeutics does not currently pay dividends.
What is Inhibikase Therapeutics’s EPS estimate?
Inhibikase Therapeutics’s EPS estimate is -0.11.
How many shares outstanding does Inhibikase Therapeutics have?
Inhibikase Therapeutics has 132,032,640 shares outstanding.
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Inhibikase Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.108. Following the earnings report the stock price went down -1.042%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
Currently, no hedge funds are holding shares in IKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inhibikase Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.00 (227.87% Upside)
$6.00 (227.87% Upside)
Hedge Fund Trend
Decreased
By 3.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.19%
12-Months-Change
Fundamentals
Return on Equity
-41.31%
Trailing 12-Months
Asset Growth
83.85%
Trailing 12-Months
Company Description
Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
IKT Stock 12 Month Forecast
Average Price Target
$6.00
▲(227.87% Upside)
Technical Analysis
Atossa Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
TScan Therapeutics
―
Ownership Overview
12.28% Insiders
5.43% Mutual Funds
67.41% Other Institutional Investors
6.67% Public Companies and
Individual Investors